If this message does not display properly, please click here to launch your browser
| How Will Physician Acceptance of Biosimilars Vary by Specialty?
— An Analyst Call from Decision Resources’ Biosimilars Advisory Service | ||||
As part of our Biosimilars Advisory Service, Decision Resources is offering an exclusive analyst call entitled How Will Physician Acceptance of Biosimilars Vary by Specialty? This analyst call is open ONLY to subscribers of Decision Resources’ Biosimilars Advisory Service. Please contact us to learn how you can purchase this service and attend the analyst call. Across major markets, the lack of automatic substitution of biosimilars will force biosimilars’ manufacturers to promote uptake among prescribing physicians. Understanding which physician specialties are concerned with which aspects of biosimilars’ production, clinical validation and marketing will be crucial to success in launching a biosimilar and/or defending a brand from biosimilar erosion. Based on our survey of 482 specialists across three countries (U.S., France and Germany) and six specialties, this analyst call will answer the following questions:
The analyst call will be presented by Product Director Michael Malecki, Ph.D. Registration: Biosimilars Advisory Service Analyst Call How Will Physician Acceptance of Biosimilars Vary by Specialty? August 18, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase the Biosimilars Advisory Service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
|||
Terms of Use | Privacy Policy | Contact Us | Careers |
||||
Michael Malecki, Ph.D., is a product director and head of biosimilars research at Decision Resources. Dr. Malecki specializes in conducting primary market research, identifying leading indicators and translating market findings into tactical and strategic objectives. Prior to joining the company, Dr. Malecki completed his doctorate in biological chemistry and molecular pharmacology at Harvard Medical School, where he was an American Heart Association Predoctoral Fellow.